vs
大都会人寿（MET）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是大都会人寿的1.0倍（$622.0M vs $600.0M），大都会人寿净利率更高（134.8% vs 34.4%，领先100.4%），大都会人寿同比增速更快（7.9% vs 4.8%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs 2.0%）
大都会人寿（MetLife）是全球规模领先的保险、年金及员工福利服务提供商之一，创立于1868年，业务覆盖超60个国家和地区，服务约9000万客户，2018年位列《财富》美国500强营收排行榜第43位。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
MET vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.0倍
$600.0M
营收增速更快
MET
高出3.1%
4.8%
净利率更高
MET
高出100.4%
34.4%
两年增速更快
RPRX
近两年复合增速
2.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $600.0M | $622.0M |
| 净利润 | $809.0M | $214.2M |
| 毛利率 | — | — |
| 营业利润率 | — | 62.4% |
| 净利率 | 134.8% | 34.4% |
| 营收同比 | 7.9% | 4.8% |
| 净利润同比 | -36.3% | 2.9% |
| 每股收益（稀释后） | $1.18 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收METRPRX
| Q4 25 | $600.0M | $622.0M | ||
| Q3 25 | $621.0M | $609.3M | ||
| Q2 25 | $604.0M | $578.7M | ||
| Q1 25 | $611.0M | $568.2M | ||
| Q4 24 | $556.0M | $593.6M | ||
| Q3 24 | $554.0M | $564.7M | ||
| Q2 24 | $558.0M | $537.3M | ||
| Q1 24 | $577.0M | $568.0M |
净利润METRPRX
| Q4 25 | $809.0M | $214.2M | ||
| Q3 25 | $896.0M | $288.2M | ||
| Q2 25 | $729.0M | $30.2M | ||
| Q1 25 | $945.0M | $238.3M | ||
| Q4 24 | $1.3B | $208.2M | ||
| Q3 24 | $1.3B | $544.0M | ||
| Q2 24 | $946.0M | $102.0M | ||
| Q1 24 | $867.0M | $4.8M |
营业利润率METRPRX
| Q4 25 | — | 62.4% | ||
| Q3 25 | — | 70.1% | ||
| Q2 25 | — | 36.3% | ||
| Q1 25 | — | 94.0% | ||
| Q4 24 | — | 60.9% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 50.2% | ||
| Q1 24 | — | -13.0% |
净利率METRPRX
| Q4 25 | 134.8% | 34.4% | ||
| Q3 25 | 144.3% | 47.3% | ||
| Q2 25 | 120.7% | 5.2% | ||
| Q1 25 | 154.7% | 41.9% | ||
| Q4 24 | 228.6% | 35.1% | ||
| Q3 24 | 242.2% | 96.3% | ||
| Q2 24 | 169.5% | 19.0% | ||
| Q1 24 | 150.3% | 0.8% |
每股收益（稀释后）METRPRX
| Q4 25 | $1.18 | $0.49 | ||
| Q3 25 | $1.22 | $0.67 | ||
| Q2 25 | $1.03 | $0.07 | ||
| Q1 25 | $1.28 | $0.55 | ||
| Q4 24 | $1.75 | $0.46 | ||
| Q3 24 | $1.81 | $1.21 | ||
| Q2 24 | $1.28 | $0.23 | ||
| Q1 24 | $1.10 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $25.6B | $618.7M |
| 总债务越低越好 | — | $9.0B |
| 股东权益账面价值 | $28.4B | $9.7B |
| 总资产 | $745.2B | $19.6B |
| 负债/权益比越低杠杆越低 | — | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资METRPRX
| Q4 25 | $25.6B | $618.7M | ||
| Q3 25 | $26.2B | $938.9M | ||
| Q2 25 | $27.5B | $631.9M | ||
| Q1 25 | $26.9B | $1.1B | ||
| Q4 24 | $25.2B | $929.0M | ||
| Q3 24 | $26.4B | $950.1M | ||
| Q2 24 | $24.6B | $1.8B | ||
| Q1 24 | $24.7B | $843.0M |
总债务METRPRX
| Q4 25 | — | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
股东权益METRPRX
| Q4 25 | $28.4B | $9.7B | ||
| Q3 25 | $28.9B | $9.6B | ||
| Q2 25 | $27.7B | $9.5B | ||
| Q1 25 | $27.5B | $9.8B | ||
| Q4 24 | $27.4B | $10.3B | ||
| Q3 24 | $30.9B | $10.3B | ||
| Q2 24 | $27.3B | $9.8B | ||
| Q1 24 | $28.5B | $9.9B |
总资产METRPRX
| Q4 25 | $745.2B | $19.6B | ||
| Q3 25 | $719.7B | $19.3B | ||
| Q2 25 | $702.5B | $18.3B | ||
| Q1 25 | $688.3B | $17.6B | ||
| Q4 24 | $677.5B | $18.2B | ||
| Q3 24 | $705.0B | $18.0B | ||
| Q2 24 | $675.7B | $17.7B | ||
| Q1 24 | $677.6B | $16.1B |
负债/权益比METRPRX
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $7.1B | $827.1M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | 8.75× | 3.86× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流METRPRX
| Q4 25 | $7.1B | $827.1M | ||
| Q3 25 | $3.6B | $702.6M | ||
| Q2 25 | $2.2B | $364.0M | ||
| Q1 25 | $4.3B | $596.1M | ||
| Q4 24 | $4.6B | $742.5M | ||
| Q3 24 | $4.2B | $703.6M | ||
| Q2 24 | $3.5B | $658.2M | ||
| Q1 24 | $2.3B | $664.6M |
现金转化率METRPRX
| Q4 25 | 8.75× | 3.86× | ||
| Q3 25 | 3.98× | 2.44× | ||
| Q2 25 | 3.00× | 12.06× | ||
| Q1 25 | 4.51× | 2.50× | ||
| Q4 24 | 3.63× | 3.57× | ||
| Q3 24 | 3.11× | 1.29× | ||
| Q2 24 | 3.69× | 6.45× | ||
| Q1 24 | 2.69× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MET
| Other | $165.0M | 28% |
| Prepaidlegalplansandadministrativeonlycontracts | $158.0M | 26% |
| Vision Fee For Service Arrangements | $140.0M | 23% |
| Administrative Service | $76.0M | 13% |
| Distribution Service | $36.0M | 6% |
| Feebasedinvestmentmanagementservices | $25.0M | 4% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
